Q-omics provides the consensus-scored CD109 profile across patient tissues and cancer cell-line models. CD109 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, CD109 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, CD109 protein abundance shows 24,528 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight STAD, HNSC, and PDAC as cancer lineages where CD109 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CD109 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CD109 survival associations across molecular data types. CD109 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (9) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CD109 RNA expression–survival associations across cancer types. High CD109 expression shows unfavorable associations in STAD, BLCA, SCLC, UVM, MESO and LGG. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for CD109 RNA expression.
This table summarizes CD109 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CD109. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CD109 shows lower tumor expression in KICH and higher tumor expression in HNSC, KIRC, THCA, LIHC and LUSC. The HNSC box plot shows higher CD109 RNA expression in tumor versus normal tissue (log2 FC = +2.030, t-test p < 0.001).
This table shows molecular features associated with CD109 in patient tissues and cancer cell lines. In patient samples, CD109 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, CD109 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BONE.
